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PAtherosclerosis
CD40 Ligand Microparticles From
Human Atherosclerotic Plaques Stimulate
Endothelial Proliferation and Angiogenesis
A Potential Mechanism for Intraplaque Neovascularization
Aurélie S. Leroyer, PHD,*† Pierre-Emmanuel Rautou, MD,*† Jean-Sébastien Silvestre, PHD,*†
Yves Castier, MD, PHD,‡ Guy Lesèche, MD, PHD,‡ Cécile Devue, BSC,*† Micheline Duriez, BSC,*†
Ralf P. Brandes, MD, PHD,§ Esther Lutgens, MD, PHD, Alain Tedgui, PHD,*†
Chantal M. Boulanger, PHD*†
Paris, France; Frankfurt-am-Main, Germany; and Maastricht, the Netherlands
Objectives Our goal was to demonstrate that microparticles (MPs) are the endogenous signal leading to neovessel forma-
tion through CD40 ligation in human atherosclerotic plaques.
Background Vulnerable atherosclerotic plaques prone to rupture are characterized by an increased number of vasa vasorum and
frequent intraplaque hemorrhage. Although inflammatory cytokines, growth factors, or CD40/CD40 ligand (CD40L)
are possible candidates, the mechanism of atherosclerotic plaque neovascularization remains unknown. Atheroscle-
rotic plaques contain large amounts of membrane-shed submicron MPs released after cell activation or apoptosis.
Methods Microparticles were isolated from endarterectomy specimens surgically obtained from 26 patients and charac-
terized by phosphatidylserine exposure and specific markers of cellular origin.
Results Plaque MPs increased both endothelial proliferation assessed by 3H-thymidine incorporation and cell number and
stimulated in vivo angiogenesis in Matrigel (BD Biosciences, San Diego, California) assays performed in wild-type and
BalbC/Nude mice, whereas circulating MPs had no effect. Microparticles from symptomatic patients expressed more
CD40L and were more potent in inducing endothelial proliferation, when compared with asymptomatic plaque MPs.
Most of CD40L MPs (93%) isolated from human plaques were of macrophage origin. Microparticle-induced endo-
thelial proliferation was impaired by CD40L or CD40-neutralizing antibodies and abolished after endothelial CD40-
ribonucleic acid silencing. In addition, the proangiogenic effect of plaque MPs was abolished in Matrigel assays per-
formed in the presence of CD40L-neutralizing antibodies or in CD40-deficient mice.
Conclusions These results demonstrate that MPs isolated from human atherosclerotic lesions express CD40L, stimulate en-
dothelial cell proliferation after CD40 ligation, and promote in vivo angiogenesis. Therefore, MPs could represent
a major determinant of intraplaque neovascularization and plaque vulnerability. (J Am Coll Cardiol 2008;52:
1302–11) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.032A
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ccepted July 28, 2008.therosclerosis is an inflammatory disease of the vascular
all, leading to lipid accumulation, macrophage infiltra-
ion, and subsequent focal thickening of the intimal layer
f arteries. Often silent and slow progressing, it becomes
ife threatening when the lesion ruptures, leading to local
See page 1312
hrombus formation, arterial occlusion, and tissue isch-
mia. Vulnerable atherosclerotic plaques prone to rupture
re characterized by an enlarged necrotic core containing
poptotic macrophages, an increased number of vasa
asorum, and more frequent intraplaque hemorrhage (1).
he network of leaky neovessels is the source of in-
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October 14, 2008:1302–11 Microparticles and Plaque Neovessel Formationraplaque hemorrhage, providing erythrocyte-derived free
holesterol within the lipid core and excessive macro-
hage infiltration, therefore promoting the transition
rom stable to unstable plaque (1). Endothelial prolifer-
tion indexes are increased in neovessels from human
ndarterectomy specimens (2), and intimal neovascular-
zation is likely arising from the adventitia where there
re numerous pre-existing vasa vasorum (3,4). Although
ngiogenesis is regulated by the combined action of various
ytokines and growth factors released by infiltrating
nflammatory cells, the exact mechanism of intraplaque
eovascularization remains unknown (1). Ligation of
D40 is a possible candidate, as CD40 and CD40 ligand
CD40L) are highly expressed in human atherosclerotic
laques, and CD40 ligation results in the expression of
everal angiogenic factors (5–9). In addition, interruption
f CD40 signaling improves plaque stability (10,11).
owever, the contribution of the CD40-CD40L path-
ay to plaque neovascularization remains speculative (1).
Advanced human atherosclerotic plaques contain large
mounts of microparticles (MPs), which are submicron
embrane vesicles released after cell activation or apo-
tosis (12–14). Microparticles harbor at their surface
ost of the membrane-associated proteins of the cells
hey stem from and are characterized by the loss of
lasma membrane asymmetry and exposure of phospha-
idylserine on their outer leaflet (15,16). Microparticles
solated from human atherosclerotic lesions are highly
hrombogenic and originate from multiple cells, includ-
ng macrophages, lymphocytes, erythrocytes, and smooth
uscle and endothelial cells (13,14). Microparticles are
o longer considered innocent bystanders since several
ecent studies point out that in vitro– generated MPs can
ffect several cellular functions, including inflammatory
nd angiogenic responses (15,16).
Therefore, we tested the hypothesis that MPs are the
ndogenous signal leading to neovessel formation through
atients’ Baseline Characteristics (n  26)
Table 1 Patients’ Baseline Characteristics (n  26)
Age (yrs) 73  2
Male subjects 85%
Symptomatic plaques 50%
Stroke 28%
Transient ischemic attack 16%
Amaurosis 6%
Clinical features
Diabetes 35%
Hypertension 69%
Smoking 54%
Dyslipidemia 65%
Treatments
Antiaggregants 100%
Statins 88%
Angiotensin-converting enzyme inhibitors 50%
Beta-blockers 35%aata are expressed as mean  SEM (age) or frequency in percentage.igation of CD40 in human ath-
rosclerotic plaques. The present
esults demonstrate that MPs
solated from human atheroscle-
otic lesions expressed CD40L,
hich stimulates endothelial cell
roliferation and promotes in
ivo neovessel formation after
D40 ligation.
ethods
P isolation from human end-
rterectomy specimens. This
tudy, which was approved by
ur hospital review board, in-
luded 26 patients undergoing
arotid endarterectomy who
ave their informed consent
efore inclusion in the study
Table 1). Microparticles were
solated from human atheroscle-
otic plaques according to a previ-
usly described procedure, which
oes not generate MPs from
ealthy human arteries (14).
Briefly, surgical samples were rapidly rinsed in cold
terile phosphate-buffered saline solution supplemented
ith 100 U/ml streptomycin and 100 U/ml penicillin,
nd atherosclerotic lesions were separated from the ap-
arently healthy vessel wall. Plaques were then thor-
ughly minced using fine scissors in a volume of fresh
ulbecco’s modified eagle medium (DMEM) (supple-
ented with 10 g/ml polymyxin B, 100 U streptomycin,
nd 100 U/ml penicillin and filtered on a 0.22-m
embrane) corresponding to 10-fold the respective
eight of each lesion in order to suspend MPs. The
esulting preparations were centrifuged first at 400 g (15
in) and then at 12,500 g (5 min) to remove cells and cell
ebris. The resulting supernatants were subsequently
sed for flow cytometry experiments. Part of this so-
alled plaque homogenate was further centrifuged at
0,500 g for 150 min at 4°C to pellet MPs. Pellets were
ently suspended in a volume of fresh DMEM in order to
btain a concentration of MPs near the concentration of
he plaque. All experiments on endothelial proliferation
ere performed with pelleted MPs resuspended in
MEM (14) and compared with the effects of DMEM
lone (vehicle). The proliferative effect of plaque MPs
as also compared with that of 0.2- and 0.1-m sterile
ltered 20,500 g supernatant obtained after pelleting
Ps from plaque homogenates.
irculating MP isolation. Circulating MPs were isolated
rom platelet-free plasma obtained by successive centrifuga-
ions of venous citrated blood drawn from the same patients,
Abbreviations
and Acronyms
AnnV  Annexin V
CD40L  CD40 ligand
COX  cyclooxygenase
DMEM  Dulbecco’s
modified eagle medium
ELISA  enzyme-linked
immunoadsorbent assay
FCS  fetal calf serum
FITC 
fluoroisothiocyanate
HUVEC  human umbilical
vein endothelial cell
IL  interleukin
MP  microparticle
PC5  phycoerythrin-
cyanin 5
PE  phycoerythrin
siRNA  small interfering
ribonucleic acid
VEGF  vascular
endothelial growth factors reported earlier (17). Briefly, citrated venous blood (5 ml)
w
5
i
t
M
c
p
p
p
f
t
a
fi
F
p
t
(
d
s
t
d
(
p
fl
C
B
C
w
f
i
i
i
C
a
a
m
d
F
P
n
m
fl
(

p
t
a
l
a
f
p
c
c
A
e
H
p
a
t
o
(
s
w
1
w
p
p
g
3
e
3
3
c
I
p
W
C
g
V
c
fi
t
c
a
w

fl
F
m
E
m
r
e
o
q
B
m
a
t
2
M
f
p
i
t
o
R
H
f
p
1304 Leroyer et al. JACC Vol. 52, No. 16, 2008
Microparticles and Plaque Neovessel Formation October 14, 2008:1302–11as centrifuged at 500 g for 15 min and then at 13,000 g for
min at room temperature. In order to obtain, after dilution
n endothelial cell medium, concentrations in MPs similar
o those present in the plasma of the patients, circulating
Ps were concentrated from platelet-free plasma using
entrifugation at 20,500 g for 150 min (4°C) and resus-
ended in a volume of plasma remaining above the MPs
ellet corresponding to one-tenth of the initial volume of
lasma. Experiments on endothelial proliferation were per-
ormed with pelleted circulating MPs and compared with
he effect of platelet-free plasma devoid of MPs (obtained
fter 20,500 g centrifugation and 0.2 then 0.1 m sterile
ltration; vehicle).
low cytometry analysis. For each patient, analyses were
erformed on the plaque homogenate (12,500 g superna-
ant) and on platelet-free plasma, as previously described
14,17). We incubated 10 l of plaque homogenate with
ifferent fluorochrome-labeled antibodies or their corre-
ponding isotype-matched immunoglobulin (Ig)G con-
rol specimens at room temperature for 30 min in the
ark. Antihuman CD154 (CD40L)-phycoerythrin (PE)
20 l/test), anti–CD4-PE (20 l/test), anti–CD41-
hycoerythrin-cyanin 5 (PC5) (10 l/test), anti–CD62P-
uoroisothiocyanate (FITC), anti–CD66b-FITC, anti–
D144-PE, and anti–CD235a-FITC were provided by
eckman Coulter (Villepinte, France). Antihuman
D14-PE conjugated and its isotype-matched IgG control
ere provided by Caltag Laboratories (Burlingame, Cali-
ornia). To determine the cellular origin of CD40LMPs,
n some experiments we used antihuman CD154-FITC or
sotype (BD Pharmingen, San Jose, California) for colabel-
ng with PE-conjugated antibodies. The antibody against
D40 was provided by R&D Systems (Lille, France). As
nti-CD40 was unconjugated, we used the polyclonal rabbit
ntimouse IgG-PC5 (Dakocytomation, Glostrup, Den-
ark) as a secondary antibody. The presence of phosphati-
ylserine at the surface of plaque MPs was assessed using
ITC-conjugated Annexin V (AnnV) (Roche Diagnostics,
aris, France) diluted in appropriate buffer (Roche Diag-
ostics) in the presence or in the absence of CaCl2 (5
mol/l final concentration), as a negative control.
Microparticles were analyzed on a Coulter EPICS XL
ow cytometer (Beckman Coulter) as previously described
14,17). A known amount of Flowcount calibrator beads (20
l, Beckman Coulter) was added to each sample just before
erforming flow cytometry analysis. Regions corresponding
o MPs were identified in forward light scatter and side-
ngle light scatter intensity dot plot representation set at
ogarithmic gain. An MP gate was defined as an event with
0.1- to 1-m diameter and then plotted on a fluorescence/
orward light scatter fluorescence dot plot to determine
ositively labeled MPs by specific antibodies. Microparticle
oncentration was assessed by comparison with Flowcount
alibrator beads (Beckman Coulter).
ssessment of cell proliferation. Endothelial cell prolif-ration was determined by 3H-thymidine incorporation. ouman umbilical vein endothelial cells (HUVECs) were
lated in 96-well plates and incubated at 37°C in a 5% CO2
tmosphere. The HUVECs (7 different donors) were ob-
ained from Promocell (Heidelberg, Germany) and cultured
n endothelial cell basal medium with a supplement pack
Promocell). All experiments were performed between pas-
ages 2 and 6. When cells reached 70% of confluence, they
ere rendered quiescent by replacing fetal calf serum (FCS)
0% by 0.1% bovine serum albumin for 24 h. Then they
ere stimulated with either MPs (20,500 g pellet resus-
ended in fresh DMEM for plaque MPs or in filtered
lasma supernatant for plasma MPs), MPs’ vehicle (20,500
supernatant), or FCS (as a positive control) during 48 h.
H-thymidine incorporation (performed in triplicate for
ach data point) was determined after addition of 1 Ci of
H-labeled thymidine per well for an additional 16 h at
7°C. Radioactivity was counted by scintillation spectros-
opy (TopCount NXT, PerkinElmer, Downers Grove,
llinois). Neutralizing antibodies used in this assay were
rovided by R&D Systems (Minneapolis, Minnesota).
e assessed antihuman CD40 (clone 82111), antihuman
D40L (clone 40804), antihuman vascular endothelial
rowth factor (VEGF)-R1 (clone 49560), antihuman
EGF-R2 (clone 89115), and their corresponding isotypic
ontrol (IgG2B, clone 20116, IgG1, clone 11711) at the
nal concentration of 5 g/ml. Pilot experiments revealed
hat higher concentrations of the isotypic control signifi-
antly impair endothelial proliferation. Inhibitors NS-398
nd LY-294006 were used at the concentration of 1 mol/l;
ortmanin was used at the concentrations of 0.1, 1, and 10
mol/l. Endothelial cell proliferation was also assessed by
ow cytometry numbering HUVECs by comparison with
lowcount calibrator beads of known concentration (Beck-
an Coulter, EPICS XL cytometer).
nzyme-linked immunoadsorbent assay (ELISA). A
edium of HUVECs exposed to plaque MPs for 48 h were
emoved and centrifuged at 500 g for 15 min in order to
liminate cell debris and then at 20,500 g for 45 min in
rder to eliminate MPs. Interleukin (IL)-8 release was
uantified with a human IL-8 ELISA kit provided by BD
iosciences (San Diego, California) according to the
anufacturer’s instructions. CD40L exposed by MPs was
lso quantified in ELISA with the Human sCD40L Quan-
ikine Kit provided by R&D Systems. VEGF release after
4-h exposure of HUVECs to MPs was quantified in
P-free medium (obtained after 20,500 g centrifugation,
ollowed by 0.1-m filtration) using antihuman VEGF
rovided by R&D Systems according to the manufacturer’s
nstructions. Control experiments evaluated VEGF concen-
ration in the medium containing the highest concentration
f MPs, but not exposed to HUVECs.
ibonucleic acid (RNA)-mediated silencing of CD40 in
UVECs. The RNA interference treatment was per-
ormed on subconfluent HUVECs plated in 96-well
lates in serum and antibiotic-free medium. Transfection
f small interfering ribonucleic acid (siRNA) (75 nmol/l
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October 14, 2008:1302–11 Microparticles and Plaque Neovessel Formationnal concentration, ON-TARGETplusSMARTpool,
at. L-008101-0 and siCONTROL Non-Targeting
iRNA#2, cat. D-001210-02-05) was performed by means
f the DharmaFECT-1 transfection reagent (Dharmacon,
nc., Chicago, Illinois), according to the manufacturer’s
nstructions. Transfection efficacy was assessed by flow
ytometry analysis of CD40 expression on HUVECs after
2 h.
atrigel assay. Ten-week-old BalbC/Nude or C57Bl/6
Charles River, L’arbresle, France) and 10-week-old
D40/-deficient female mice (10) (Department of Pa-
hology, University of Maastricht, Maastricht, the Nether-
ands) received in their back a 0.5-ml subcutaneous injection
f Matrigel containing either 3  106 plaque MPs (6,000
Ps/l final concentration) or the equivalent volume of
laque MP supernatant, according to previously described
rotocol (18). After the injection, the Matrigel rapidly
ormed a subcutaneous plug that was left for 7 days. On day
, mice were euthanized, and the skin of the mouse was
asily pulled back to expose the Matrigel. Plugs were then
emoved and fixed with 4% formaldehyde at 4°C for 12 h,
mbedded in paraffin, sectioned, and stained with Masson
richrome. Three successive sections of 5 m, at the top,
iddle, and bottom of each plug, were then examined by an
nvestigator unaware of the status of the material (10,
20, and 40 magnification, Olympus BH-2, Leica, Paris,
rance). For each localization (top, middle, bottom) in the
lug, 3 sections were analyzed, which led to an average of 9
cquisitions for each mouse. Neovessel formation was mea-
ured by means of 3 scores. Score 0 characterized the
bsence of cells in Matrigel section, score 1 corresponded to
he presence of endothelial cells, and score 2 was defined by
he presence of erythrocytes into the Matrigel plug. The
resence of endothelial cells was confirmed using antimouse
D31-FITC (5 g/ml, BD Biosciences) or FITC-labeled
SL-1-isolectin B4 (25 g/ml, Vector Lab, Paris, France).
rythrocytes present in Matrigel plugs were identified using
ntimouse PE-labeled TER-119 antibody (2 g/ml, BD
iosciences).
tatistical analysis. Data are presented as mean  SEM,
xcept for the cellular origin of plaque MPs shown in
able 1. Wilcoxon tests for nonparametric paired samples
nd Mann-Whitney U tests for independent samples
ere used. Differences were considered significant with a
alue of p  0.05.
esults
laque MPs induce in vitro endothelial cell prolifera-
ion. Endothelial cell proliferation, evaluated by 3H-
hymidine incorporation in subconfluent quiescent
UVECs, was markedly elevated after exposure to increas-
ng concentrations of plaque MPs (50 to 20,000 AnnV
Ps/l) for 48 h, whereas MPs’ vehicle (20,500 g super-
atant) had no effect on proliferation (n  12) (Fig. 1A).
xposure to plaque MPs (6,000 AnnVMPs/l; 48 h) led 0o a 2.5 0.5-fold increase in endothelial cell number when
ompared with that of the vehicle’s effect (n  5) (Fig. 1B).
his proliferative effect was also observed with human aortic
ndothelial cells (data not shown). The maximal 3H-
hymidine incorporation induced by plaque MPs at the
oncentration of 10,000 AnnV MPs/l (3.8  1.0-fold
ncrease) was not different from that of 10% FCS (used as a
ositive control; p  0.44; n  8). In experiments per-
ormed at the concentration of 6,000 AnnV MPs/l, we
bserved that the proliferative effect was more potent for
Ps obtained from symptomatic than asymptomatic pa-
ients (100  7% vs. 67  13% of the effect of FCS, n  6
ach; p  0.03) (Fig. 1C). Further experiments were
erformed at the suboptimal concentration of 6,000
nnV MPs/l.
We also investigated the potential proliferative effects of
irculating MPs isolated from the same patients on endo-
helial cells. This effect was investigated for a concentration
f 1,000 AnnVMPs/l, which is within the range of MP
lasma concentrations in these patients (14). There was no
tatistical difference in 3H-thymidine incorporation be-
ween circulating MPs when compared with that in the
ehicle (platelet-free plasma devoid of MPs; p  0.46; n 
). Moreover, when comparing similar concentrations of
Ps (1,000 AnnV MPs/l) obtained either from the
laque or the blood of the same patient, we observed that
H-thymidine incorporation induced by plaque MPs was
reater than that of plasma MPs (3.6  0.9-fold increase;
 6; p 0.03). These results suggest that the proliferative
ffect of MPs is specific to MPs isolated from atheroscle-
otic plaque.
echanism of plaque MP-induced endothelial cell pro-
iferation. Because plaque MPs were mostly of leukocyte
rigin (14), we investigated the possible contribution of
icotinamide adenine dinucleotide phosphate oxidase-
ependent reactive oxygen species to MP-induced 3H-
hymidine incorporation in endothelial cells. Apocynin (1
mol/l) had no significant effect (n 6; MPs 128 27%
f FCS; MPs apocynin 108 25% of FCS; p 0.13),
nd Western blot analysis of plaque MPs using anti–p22-,
47-, p67-, and gp91-phox antibodies demonstrated that
laque MPs only express detectable amounts of the mem-
rane subunits p22- and gp91-phox but not the cytosolic
ubunits p67- and p47-phox of nicotinamide adenine dinu-
leotide phosphate oxidase (n  5, data not shown).
The possible contribution of CD40/CD40L to plaque
P-induced endothelial proliferation was then investi-
ated. Endothelial cells expressed CD40, but not CD40L,
nd exposure to plaque MPs dose-dependently stimulated
ndothelial CD40 expression (Figs. 2A and 2B). Although
Ps’ abundance and cellular origin were not different
etween asymptomatic and symptomatic patients (n  13
ach; p  0.05) (Table 2) as reported earlier (14), plaque
rom symptomatic patients expressed more CD40L MPs
han those from asymptomatic patients (n  13 each; p 
.01) (Fig. 2D). The ELISA assay confirmed the presence
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Microparticles and Plaque Neovessel Formation October 14, 2008:1302–11f CD40L on MPs, while it was undetectable on the 20,500
supernatant obtained after pelleting MPs from plaque
omogenates (data not shown). Plaque MPs did not harbor
D40, and endothelial cells, used between passages 2 and 6,
id not express CD40L. However, CD40L expression was
easurable in HUVECs after tumor necrosis factor-alpha
timulation (Figs. 2A and 2B). We observed that 93  4%
f CD40L MPs are also positive for CD14, demonstrat-
ng that CD40LMPs are mostly of macrophage origin in
he human plaque. We could also exclude that CD40L
Ps derived from platelets, as we did not detect platelet
Ps in human atherosclerotic plaques (absence of CD41,
D42, and CD62CD144-labeling of plaque MPs)
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Figure 1 Plaque MPs Induce In Vitro Endothelial Cell Proliferat
(A) Plaque microparticles (MPs) induce a dose-dependent increase in 3H-thymidine
vehicle (Dulbecco’s modified eagle medium [DMEM]) and the 20,500 g supernatan
induce a dose-dependent increase in endothelial cell number (n  6). (C) Plaque
liferation than those from asymptomatic (AS) patients (n  6). FCS  fetal calf se14). Circulating MPs obtained from the same patients also 0xpressed CD40L, but at much lower levels than those
ound in plaque homogenates (plasma: 959  266
D40L MPs/l; plaque homogenates: 96,252  19,565
D40L MPs/l; p  0.001; n  22). Unlike plaque
Ps, no difference of CD40L expression was observed in
irculating MPs when comparing plasmas from symptom-
tic and asymptomatic patients (p  0.87).
Then, we examined the possible contribution of CD40
igation in MP-induced endothelial proliferation using
eutralizing antibodies and their corresponding isotypic
gGs as controls. Exposure of plaque MPs to an anti-
D40L neutralizing antibody decreased by 48  17%
P-induced 3H-thymidine incorporation (n  12; p 
6 10 20 FCS
10%
Sn
L
n.s.
3
H
 t
h
ym
ni .
co
rp
o
ra
ti
o
n
( 
%
o
f 
F
C
S
ef
fe
ct
) C
0
20
40
60
80
100
120
AS Sympto
*
poration in human umbilical vein endothelial cells (HUVECs), whereas both MPs’
obtained after pelleting MPs from plaque homogenate did not. (B) Plaque MPs
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ion
incor
t (Sn)
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October 14, 2008:1302–11 Microparticles and Plaque Neovessel FormationD40 –neutralizing antibody decreased it by 32  2%,
nd the combination of these 2 neutralizing antibodies
ecreased it by 63  16% (n  6 each, p  0.04 and 0.04,
espectively) (Fig. 3A). Higher concentrations of neutral-
zing antibodies were also tested. Unfortunately, these
esults are difficult to interpret as the corresponding
sotypes significantly modified endothelial proliferation
n their own (data not shown).
Therefore, we investigated endothelial proliferation after
xposure to plaque MPs using siRNA-CD40–transfected
C
A
Figure 2 HUVECs Exposed to Plaque MPs Express CD40 and P
(A) Representative flow cytometry fluorescence histogram showing the absence of
tions and after exposure to plaque MPs (right). The black line corresponds to the
erythrin-cyanin 5 (PC5) labeling. Endothelial CD40 expression is augmented when
of HUVECS with small interfering ribonucleic acid (siRNA) abolished PC5 labeling (
exposed to increasing numbers of plaque MPs (n  3). (C) Representative flow cy
and its absence on endothelial cells under basal conditions or after exposure to p
CD40L-phycoerythrin (PE)–positive MPs. Tumor necrosis factor (TNF)-stimulated HU
line, right). (D) Plaque MPs from Sympto patients express more CD40L than thos
Cellular Origins of MPs Isolated From HumanAtherosclerotic Plaque Between Asymptomatic
Table 2 Cellular Origins of MPs Isolated FroAtherosclerotic Plaque Between As
Asymptomatic Patients
Lymphocyte (CD4) MPs 19,155 (1,613–83,6
Macrophage (CD14) MPs 36,649 (16,939–158
Granulocyte (CD66b) MPs 16,853 (7,583–69,7
Endothelial (CD144) MPs 24,979 (9,382–117,
Erythrocyte (CD235a) MPs 70,974 (0–292,836)
SMC (SMA) MPs 40,518 (20,523–68,Median values and ranges are expressed as n/mg lesion.
MP  microparticle; SMC  smooth muscle cell.UVECs. CD40-silenced HUVECs no longer expressed
D40 as demonstrated by flow cytometry analysis (Fig.
A); however, 3H-thymidine incorporation induced by FCS
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referential inhibitor of COX-2, NS-398 (106 mol/l), did not
ffect plaque-MP-induced thymidine incorporation (n  6;
,017 95 cpm vs. 1,286 137 cpm with NS-398; p 0.17)
Fig. 3C). However, endothelial proliferation was impaired by
ither Wortmanin (1 mol/l) (n  5; 6,876  1,841 cpm vs.
,526 633 cpm; p 0.04) or LY294002 (1 mol/l) (n 7;
,444  304 cpm vs. 392  116 cpm; p  0.02), both
nhibitors of PI3-kinase/Akt. An anti–VEGF-R2 blocking
ntibody also significantly reduced endothelial cell proliferation
n  3; 20% inhibition; p  0.04) (n  6; p  0.11) (Fig.
D). Moreover, exposure of HUVECs to increasing concen-
rations of plaque MPs augmented VEGF release, whereas
evels of VEGF were almost undetectable in plaque MPs
Fig. 3E).
laque MPs induced in vivo angiogenesis. In wild-type
Figure 4 Plaque MPs Induce In Vivo CD40L-Dependent Neoves
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Ps was similar to that of recombinant CD40L in this
odel (n  6; p  0.47) (Fig. 4C).
In order to confirm the role of CD40 ligation, the
atrigel assay was also performed in CD40/ mice; the
n vivo proliferative effect was abolished in these mice (n 
; p  0.007 when compared with the effect of MPs in
ild-type mice). Moreover, effects of plaque MPs in CD40-
eficient mice were not different from that of vehicle (MPs
upernatant; p 0.89) (Fig. 4C). These results demonstrate
hat CD40 signaling mediates the ability of plaque MPs to
nduce formation of neovessels in mice.
iscussion
he present study demonstrates for the first time that
hed-membrane MPs isolated from human atherosclerotic
esions stimulate endothelial cell proliferation and promote
n vivo neovessel formation after CD40 ligation. The
ndothelial proliferative effect of plaque MPs was more
ronounced when MPs were isolated from symptomatic
atients compared with that seen in asymptomatic patients,
nd this finding was associated with an increased number of
D40L MPs in these patients. Therefore, accumulation
f MPs in atherosclerotic lesions may represent an endog-
nous signal for atherosclerotic plaque neovascularization
nd vulnerability.
Shed-membrane vesicles have been observed in situ in
uman atherosclerotic plaque where they colocalize with
arkers of cellular apoptosis (12,13). Although very little is
nown regarding the mechanisms leading to their forma-
ion, they may result from cell plasma membrane budding
fter inflammation of the vessel wall leading to activation or
poptosis of cells from the vascular wall, as indicated by
heir multiple cellular origins (14,16). Accumulation of
xidized lipids and apoptotic cells in atherosclerotic lesions
ikely slows down efficient MP phagocytosis and removal by
acrophages. Plaque MPs are highly thrombogenic and,
herefore, contribute to thrombus formation when the
esion ruptures (13,14,21). However, apart from their role in
hrombus formation, no other biological effect has been
eported so far for MPs isolated from human atherosclerotic
laques. In order to investigate the possible biological
ctivities of plaque MPs, we recently reported a method to
solate MPs from human atherosclerotic lesions, and we
emonstrated that the procedure did not generate MPs
rom healthy human arteries (14).
In vitro studies indicate that MPs can no longer be taken
imply as a marker of cell activation or apoptosis; several
eports demonstrate that shed-membrane MPs can dissem-
nate information to neighboring or remote cells (15,16).
or instance, MPs of different cellular origin stimulate
roinflammatory responses in endothelial cells (22–24). In
ddition, endothelial-, platelet-, and tumor-cell–derived
Ps are capable of either promoting or inhibiting angio-
enesis through reactive oxygen species, metalloproteinases, wnd growth factors such as VEGF or sphingomyelin (25–
8). However, these studies were performed using in vitro–
enerated MPs, which may not reflect the biological activity
f MPs found in vivo. Indeed, studies analyzing MP
omposition demonstrate that both lipid and protein frac-
ions vary greatly depending on the stimulus initiating their
esiculation (29–31). We demonstrate here that MPs iso-
ated from human atherosclerotic plaques strongly stimulate
ndothelial cell proliferation to the same level as FCS,
eflecting their high proliferative effect. This effect is specific
or MPs isolated from human plaque, because an equivalent
oncentration of MPs isolated from the blood of the same
atients did not affect endothelial proliferation. Further-
ore, this effect of plaque MPs on endothelial proliferation
as not only observed in vitro but was also confirmed in vivo
y the formation of neovessels in Matrigel assays in mice.
oreover, an important finding is that MPs isolated from
ymptomatic plaques were more potent than those from
symptomatic plaques. Taken all together, these findings
upport the concept that in atherosclerotic lesions, MPs
ould determine neovascularization and may favor plaque
nstability.
Although angiogenesis is regulated by the combined
ction of various cytokines and growth factors released by
nfiltrating inflammatory cells, the exact mechanism of
eovessel formation in atherosclerotic plaque remains un-
nown (1). We examined the possible role of CD40 ligation
n this process. Indeed, both CD40 and CD40L are highly
xpressed in human atherosclerotic plaques, and CD40
igation stimulates endothelial proliferation and angiogene-
is (5–9). Furthermore, in vivo blockade of CD40 signaling
mproves plaque stability (10,11). We demonstrate in the
resent study a crucial role of CD40 ligation in the
roliferative effect of plaque MPs both in vitro and in vivo.
e show that CD40L is bound to macrophage-derived
Ps isolated from human atherosclerotic plaques, and even
ore so to MPs obtained from symptomatic patients, and
hat CD40L interaction with endothelial CD40 mediates
he proliferative effect of MPs isolated from human plaque.
urthermore, we demonstrate here that in vivo neovessel
ormation induced by plaque MPs requires the presence of
unctional CD40 in mice. Several intracellular pathways
ould mediate the proliferative effect of CD40 ligation on
ndothelial cells under the present experimental conditions
5–9). The lack of effect of a COX-type 2 preferential
nhibitor rules out the possible contribution of COX-2 in
P-induced proliferation (19). Furthermore, exposure of
ndothelial cells to plaque MPs did not affect the release of
L-8, which is another possible mediator of CD40 ligation
roliferative effects on endothelial cells (20). However, the
nhibitory effect of the PI3-kinase/Akt inhibitor and that of
he VEGF-R2–neutralizing antibodies supports a role for
EGF and the PI3-kinase/Akt in the endothelial prolifer-
tive effect of plaque MPs through ligation of CD40. These
ndings are in agreement with previous studies performed
ith recombinant CD40L (7–9).
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he present study reveals MPs as potential endogenous
riggers of neovascularization and growth of atherosclerotic
laque. In addition, we demonstrated in advanced and
omplex symptomatic human atherosclerotic plaque that
heir deletery proangiogenic effect is augmented and could
arry on the vicious circle of plaque instability: more
poptosis generating more MPs, contributing to neovascu-
arization, and favoring intraplaque hemorrhage, lesion
rowth, and macrophage apoptosis.
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